HLS is dedicated to the stewardship of branded pharmaceuticals through their life cycles post - exclusivity.
HLS Therapeutics has raised $78.6M in total funding. The most recent round was Post-IPO Debt. The last funding was announced in August 2024.
HLS Therapeutics's investors include Royal Bank of Canada, JP Morgan Chase, National Bank of Canada, Toronto Dominion Bank Group, Silicon Valley Bank.
HLS Therapeutics is headquartered in Caledon, Canada.
HLS is dedicated to the stewardship of branded pharmaceuticals through their life cycles post - exclusivity.
HLS Therapeutics is at the Post-IPO Debt stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"HLS Therapeutics — Funding & Investors." VCBacked, August 20, 2024, https://www.vcbacked.co/company/hls-therapeutics. Accessed July 20, 2026.
VCBacked. (2024). HLS Therapeutics — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/hls-therapeutics
{{cite web |title=HLS Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/hls-therapeutics |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated